Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU completes Meridia review

Executive Summary

EU Committee for Proprietary Medicinal Products "issued a positive opinion reaffirming the favorable risk/benefit profile of sibutramine," Abbott announces June 27. The committee reviewed the obesity drug (Meridia in the U.S.) at the request of Italian Health Ministry after the agency suspended approval of sibutramine. Abbott expects FDA to respond by the fall to a petition from Public Citizen's Health Research Group asking that Meridia be withdrawn (1"The Pink Sheet" June 17, p. 16)...

You may also be interested in...

Meridia Growth Forecast Is 50% In 2002, Despite Italian Withdrawal – Abbott

Abbott's revised forecast for the anti-obesity agent Meridia (sibutramine) still assumes a 50% increase in worldwide sales for 2002

P&G Begins US Price Increases In Baby And Feminine Care, Could Expand To Health, Beauty

P&G plans up to double-digit price increases in US baby care, feminine care and adult incontinence and will analyze raw material costs and foreign exchange impacts in its other product categories for other pricing changes.

Vertex’s Price Tag For Taking More Control Of CRISPR-Partnered Candidate: At Least $900m

Vertex and partner CRISPR Therapeutics hope CDX001 can offer a single-use curative regimen for sickle cell disease and beta thalassemia patients. A regulatory filing is possible within 18-24 months.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts